☆ 4.5 Article

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis

BMJ-BRITISH MEDICAL JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Michael Bonelli et al.

Summary: This study found that an additional booster vaccination is effective and safe for non-seroconverted patients after receiving conventional COVID-19 vaccination. Both vector and mRNA vaccines have comparable efficacy in enhancing humoral and cellular immune response, which is particularly important for immunosuppressed patients.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart et al.

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

Thiago Cerqueira-Silva et al.

Summary: This Brazilian study aimed to estimate the effectiveness of CoronaVac and a booster dose of BNT162b2 vaccine against COVID-19 infection and severe outcomes. The study found that CoronaVac had a 55% effectiveness against infection and 82.1% effectiveness against severe outcomes 14-30 days after the second dose. However, the effectiveness decreased to 34.7% against infection and 72.5% against severe outcomes over 180 days after the second dose. A BNT162b2 booster dose administered 6 months after CoronaVac improved the effectiveness to 92.7% against infection and 97.3% against severe outcomes. Older individuals had lower protection after the second dose but similar protection after the booster.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Hung Fu Tseng et al.

Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.

NATURE MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Shirley Collie et al.

Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Lisa M. Dunkle et al.

Summary: The NVX-CoV2373 vaccine has shown to be safe and highly effective in preventing Covid-19, with a vaccine efficacy of 90.4% against reverse-transcriptase-polymerase-chain-reaction-confirmed cases and 100% efficacy against moderate-to-severe disease. The vaccine also demonstrated high efficacy against various variants of the virus.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

J. Sadoff et al.

Summary: The Ad26.COV2.S vaccine was found to be 52.9% effective against moderate to severe-critical Covid-19 after a single dose, with protection lasting for at least 6 months. Efficacy varied depending on the Covid-19 variant, but higher protection was observed against severe cases, medical intervention, and death compared to other outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

E. B. Walter et al.

Summary: A regimen of two 10-mu g doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children aged 5 to 11 years.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

S. M. Olson et al.

Summary: The study examined the effectiveness of the BNT162B2 vaccine in preventing hospitalization and ICU admission in adolescents. The results demonstrated that full vaccination significantly reduced the risk of hospitalization and ICU admission.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review

Ibrahim Mohammed et al.

Summary: This article compares the efficacy and effectiveness of seven COVID-19 vaccines through a systematic review, revealing that these vaccines have successfully reduced infection rates, severity, hospitalization, and mortality. The full-dose regimen of the Pfizer/BioNTech vaccine shows the highest effectiveness against various variants.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Article Infectious Diseases

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden

Jonas Bjork et al.

Summary: The study conducted in Southern Sweden found that the effectiveness of the BNT162b2 vaccine against COVID-19 was 86% after the second dose, but only 42% after the first dose. Additionally, individuals with a prior positive test had a 91% effectiveness against new infection when unvaccinated.

INFECTIOUS DISEASES (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Jill M. Ferdinands et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

Anne M. Hause et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population

Adeel A. Butt et al.

Summary: In this large national study, it was found that receiving a third dose of an mRNA vaccine significantly improved vaccine effectiveness in preventing symptomatic infection and acute care hospitalizations in veterans before the emergence of the Omicron variant.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Virology

A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine

Lei Yue et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Efficiency decreases

Halane Vaillant-Roussel et al.

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Article Infectious Diseases

Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study

Devashish Desai et al.

Summary: This study evaluates the effectiveness of the BBV152 vaccine against symptomatic SARS-CoV-2 infection. The results show that two doses of BBV152 vaccine can significantly reduce the odds of infection, particularly when administered at least 14 days before testing. The study supports the continued rollout of this vaccine and emphasizes the importance of non-pharmacological interventions.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Yinon M. Bar-On et al.

Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Ori Magen et al.

Summary: The use of a fourth dose of BNT162b2 vaccine in Israel starting on January 3, 2022, has shown significant reductions in infection rate, symptomatic infection, hospitalization, and Covid-19-related deaths by February 18.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Eduardo Hermosilla et al.

Summary: A cohort analysis from Catalonia shows that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two doses of ChAdOx1.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Medicine, General & Internal

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Ainsley Ryan Yan Bin Lee et al.

Summary: This systematic review and meta-analysis compared the efficacy of covid-19 vaccines between immunocompromised and immunocompetent individuals. The results showed that immunocompromised patients, especially organ transplant recipients, had significantly lower rates of seroconversion after covid-19 vaccination. A second dose of the vaccine consistently improved seroconversion in all patient groups, although the improvement was smaller for organ transplant recipients. Targeted interventions, including a third dose (booster) of the vaccine, should be performed for immunocompromised patients.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Health Care Sciences & Services

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study

Sara Y. Tartof et al.

Summary: This study evaluated the effectiveness of a third dose of the BNT162b2 vaccine in a large US health system. The results showed that after receiving only two doses, the protection against infection declined over time but remained high against hospitalization. The three-dose vaccine showed better effectiveness, providing comparable or better protection against SARS-CoV-2 infections and hospital admissions compared to two doses.

LANCET REGIONAL HEALTH-AMERICAS (2022)

Add to Collection

Article Health Care Sciences & Services

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

Thiago Cerqueira-Silva et al.

Summary: This study analyzes the impact of age on the effectiveness of COVID-19 vaccines and finds that vaccine effectiveness decreases with increasing age. Although both vaccines provide some level of protection against infection, hospitalization, and death, they are more effective in individuals under 79 years of age.

LANCET REGIONAL HEALTH-AMERICAS (2022)

Add to Collection

Article Health Care Sciences & Services

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study

Katia J. Bruxvoort et al.

Summary: Background Phase 3 trials have shown that mRNA-1273 is highly effective in preventing COVID-19. A cohort study conducted at Kaiser Permanente Southern California (KPSC) found that mRNA-1273 is also highly effective in preventing COVID-19 infection and severe disease in the real world. The study showed that the vaccine has a VE of 87.4% against COVID-19 infection, 95.8% against COVID-19 hospitalization, and 97.9% against COVID-19 hospital death.

LANCET REGIONAL HEALTH-AMERICAS (2022)

Add to Collection

Review Medicine, General & Internal

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

Daniel R. Feikin et al.

Summary: This study systematically reviewed the duration of protection provided by COVID-19 vaccines against various clinical outcomes. The findings indicate that the effectiveness or efficacy of the vaccines decreased from 1 to 6 months after full vaccination, but remained high against severe disease. Evaluating the effectiveness or efficacy of vaccines beyond 6 months is crucial for updating vaccine policies.

LANCET (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021

Dan Wu et al.

Summary: In an outbreak from a hospital setting, completion of primary vaccination with inactivated COVID-19 vaccines reduces the risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Partial vaccination is ineffective, and completion of two doses of the primary vaccination is necessary for protection from Delta.

CHINA CDC WEEKLY (2022)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

Ivan Martinez-Baz et al.

EUROSURVEILLANCE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella et al.

Summary: The study reported the clinical efficacy of the BBV152 vaccine against COVID-19 infection in Indian adults. The vaccine demonstrated high efficacy in preventing laboratory-confirmed symptomatic COVID-19 and was well tolerated with no safety concerns raised in this interim analysis.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents

Ben Y. Reis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Ann R. Falsey et al.

Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Review Multidisciplinary Sciences

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Victoria Rotshild et al.

Summary: New COVID-19 vaccines from Pfizer and Moderna showed the highest efficacy in preventing symptomatic COVID-19 in adults. There was no significant difference in the prevention of symptomatic disease among the elderly population. mRNA-1273 and Gam-COVID-Vac vaccines were associated with a higher probability of protection against severe COVID-19 compared to other vaccines.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

Katia J. Bruxvoort et al.

Summary: The study evaluated the effectiveness of mRNA-1273 vaccine against SARS-CoV-2 variants, especially the delta variant, by time since vaccination. Two doses of the vaccine showed high effectiveness against all variants, with a decline in effectiveness against delta variant over time. One dose of the vaccine also demonstrated moderate effectiveness against delta infection.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data

Aharona Glatman-Freedman et al.

Summary: The BNT162b2 vaccine in Israel showed high effectiveness in preventing new SARS-CoV-2 cases. Effectiveness of the vaccine develops more slowly in individuals over 80 years old. Vaccination reduces complications and death in breakthrough cases.

EBIOMEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Immunology

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

Nan-Chang Chiu et al.

Summary: The study showed that heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants demonstrated robust immunogenicity and tolerable reactogenicity, along with stronger T cell responses. It suggests that heterologous vaccination is a viable strategy to combat COVID-19, but further research is needed to confirm its benefits and determine the optimal combinations, doses, and intervals.

EXPERT REVIEW OF VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Infectious Diseases

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Marie Tre-Hardy et al.

Summary: A study on mRNA-1273 vaccine recipients showed a significant decrease in antibody levels after 6 months, especially in individuals who had not previously been vaccinated. In a supply-limited environment, it is recommended to prioritize the third dose for seronegative individuals prior to vaccination.

JOURNAL OF INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Madhumita Shrotri et al.

Summary: Single-dose vaccination with BNT162b2 and ChAdOx1 vaccines provides substantial protection against infection in older adults from 4-7 weeks after vaccination and might reduce SARS-CoV-2 transmission. However, the risk of infection is not eliminated, highlighting the ongoing need for non-pharmaceutical interventions to prevent transmission in long-term care facilities.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Kashif Ali et al.

Summary: The study demonstrates that the mRNA-1273 vaccine has good safety profile in adolescents aged 12 to 17 years, with immune response similar to that in young adults. It also proves the efficacy of the vaccine in preventing Covid-19 in this age group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Peter Nordstrom et al.

Summary: The study suggests that heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and mRNA vaccines is an effective alternative to increase population immunity against Covid-19, with higher effectiveness compared to homologous vaccination. These findings could have significant implications for vaccination strategies and logistics in the battle against the Covid-19 pandemic.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Article Multidisciplinary Sciences

Evaluating the Quality of Evidence from a Network Meta-Analysis

Georgia Salanti et al.

PLOS ONE (2014)

Add to Collection

Article Medicine, General & Internal

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

Milo A. Puhan et al.

BMJ-BRITISH MEDICAL JOURNAL (2014)

Add to Collection

Article Mathematical & Computational Biology

Incorporating data from various trial designs into a mixed treatment comparison model

Susanne Schmitz et al.

STATISTICS IN MEDICINE (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.